[TITLE]European healthcare stocks surge as U.S. Pfizer deal reduces some uncertainty:
[TEXT]

[Source link]: https://biztoc.com/x/160dbf9a05091978


===== Company info for companies mentioned in news =====

Company name: pfizer
symbol: PFE
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759716018
name: pfizer
------------------------------------------------------------------

================================================================================

[TITLE]European healthcare stocks surge as U.S. Pfizer deal reduces some uncertainty:
[TEXT]

[Source link]: https://biztoc.com/x/160dbf9a05091978


===== Company info for companies mentioned in news =====

Company name: pfizer
symbol: PFE
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759716018
name: pfizer
------------------------------------------------------------------

================================================================================

[TITLE]BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market:
[TEXT]
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best stocks to buy under $20. On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) business to Neopharmed Gentili. The transaction is valued at $250 million upfront, subject to customary purchase price adjustments, with the potential for BioCryst to receive up to $14 million in future milestones based on sales in Central and Eastern Europe.

The divestiture immediately improves BioCryst’s operating margin, as the European business was ~breakeven on a direct basis. BioCryst will now focus on driving ORLADEYO sales in the US, while Neopharmed Gentili will lead commercialization across Europe, retaining the European commercial organization built by BioCryst for operational continuity.

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

Despite the exclusion of European revenue after the close, BioCryst remains on track to meet the upper half of its 2025 revenue guidance range of $580 million to $600 million.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is a biotechnology company that develops oral small-molecule and injectable protein therapeutics to treat rare diseases.

While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.
[Source link]: https://finance.yahoo.com/news/biocryst-sells-european-orladeyo-business-205450678.html


[TITLE]Sanofi $SNY Shares Sold by Greenleaf Trust:
[TEXT]
Greenleaf Trust decreased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 19.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,642 shares of the company’s stock after selling 2,032 shares during the period. Greenleaf Trust’s holdings in Sanofi were worth $417,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Sanofi by 124.0% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock worth $1,344,000 after acquiring an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC grew its stake in shares of Sanofi by 130.5% in the first quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock worth $568,000 after acquiring an additional 5,794 shares in the last quarter. Ballentine Partners LLC grew its stake in shares of Sanofi by 68.7% in the first quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock worth $1,445,000 after acquiring an additional 10,617 shares in the last quarter. Voya Investment Management LLC grew its stake in shares of Sanofi by 11.6% in the first quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock worth $11,460,000 after acquiring an additional 21,540 shares in the last quarter. Finally, Sowell Financial Services LLC acquired a new position in shares of Sanofi in the first quarter worth $328,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Get Sanofi alerts:

Sanofi Price Performance

Shares of SNY opened at $50.90 on Friday. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12. The stock has a market cap of $124.99 billion, a PE ratio of 12.24, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The firm has a fifty day moving average price of $48.19 and a 200 day moving average price of $50.09.

Wall Street Analysts Forecast Growth

Sanofi ( NASDAQ:SNY Get Free Report ) last announced its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The company had revenue of $11.34 billion during the quarter, compared to analysts’ expectations of $9.91 billion. During the same period last year, the firm earned $1.73 earnings per share. Sanofi’s revenue was down 7.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Several equities research analysts have recently issued reports on the stock. Morgan Stanley raised shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $56.00 to $58.00 in a research report on Monday, September 8th. Wall Street Zen raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Sanofi in a research report on Saturday, September 27th. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “hold” rating to a “buy” rating in a research report on Tuesday, September 2nd. Finally, Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, Sanofi currently has a consensus rating of “Buy” and a consensus price target of $62.67.

View Our Latest Report on Sanofi

Sanofi Profile

(Free Report)

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

Recommended Stories

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NASDAQ:SNY – Free Report).

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/10/04/sanofi-sny-shares-sold-by-greenleaf-trust/


[TITLE]Public Employees Retirement System of Ohio Acquires 70,879 Shares of Bausch Health Cos Inc. $BHC:
[TEXT]
Public Employees Retirement System of Ohio boosted its holdings in Bausch Health Cos Inc. (NYSE:BHC – Free Report) by 44.0% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 232,026 shares of the company’s stock after purchasing an additional 70,879 shares during the period. Public Employees Retirement System of Ohio’s holdings in Bausch Health Cos were worth $1,544,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of BHC. Range Financial Group LLC grew its position in shares of Bausch Health Cos by 12.8% in the 1st quarter. Range Financial Group LLC now owns 140,464 shares of the company’s stock valued at $909,000 after acquiring an additional 15,930 shares during the period. Wealthquest Corp bought a new position in shares of Bausch Health Cos in the 1st quarter valued at
[Source link]: https://www.etfdailynews.com/2025/10/04/public-employees-retirement-system-of-ohio-acquires-70879-shares-of-bausch-health-cos-inc-bhc/


[TITLE]Roche (OTCMKTS:RHHBY) Upgraded at Hsbc Global Res:
[TEXT]
Roche (OTCMKTS:RHHBY – Get Free Report) was upgraded by equities researchers at Hsbc Global Res from a “hold” rating to a “strong-buy” rating in a report released on Thursday,Zacks.com reports.

Separately, HSBC upgraded Roche from a “hold” rating to a “buy” rating and set a $50.00 price objective on the stock in a research report on Thursday. Three investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $50.00.

Get Roche alerts:

Check Out Our Latest Research Report on Roche

Roche Trading Up 1.3%

Institutional Inflows and Outflows

OTCMKTS RHHBY opened at $45.30 on Thursday. The company’s 50 day simple moving average is $40.76 and its two-hundred day simple moving average is $40.27. Roche has a 1 year low of $34.10 and a 1 year high of $45.46.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Accent Capital Management LLC bought a new position in Roche in the first quarter valued at $35,000. First Horizon Advisors Inc. increased its position in shares of Roche by 81.2% during the 2nd quarter. First Horizon Advisors Inc. now owns 1,843 shares of the company’s stock valued at $75,000 after purchasing an additional 826 shares during the last quarter. Atlas Capital Advisors Inc. purchased a new position in shares of Roche during the 1st quarter valued at about $140,000. Enterprise Financial Services Corp bought a new stake in Roche in the 2nd quarter worth approximately $208,000. Finally, FineMark National Bank & Trust purchased a new stake in Roche in the second quarter worth approximately $210,000.

Roche Company Profile

(Get Free Report)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

See Also

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/10/04/roche-otcmktsrhhby-upgraded-at-hsbc-global-res/


===== Company info for companies mentioned in news =====

Company name: bausch health
symbol: BHC
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759716022
name: bausch health
------------------------------------------------------------------

Company name: biocryst pharmaceuticals
name: biocryst pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=biocryst+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: roche
symbol: ROG.SW
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759716023
name: roche
------------------------------------------------------------------

Company name: sanofi
symbol: SNW.F
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759716024
name: sanofi
------------------------------------------------------------------

================================================================================

[TITLE]BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market:
[TEXT]
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is one of the best stocks to buy under $20. On October 1, BioCryst Pharmaceuticals announced the successful completion of the previously announced sale of its European ORLADEYO (berotralstat) business to Neopharmed Gentili. The transaction is valued at $250 million upfront, subject to customary purchase price adjustments, with the potential for BioCryst to receive up to $14 million in future milestones based on sales in Central and Eastern Europe.

The divestiture immediately improves BioCryst’s operating margin, as the European business was ~breakeven on a direct basis. BioCryst will now focus on driving ORLADEYO sales in the US, while Neopharmed Gentili will lead commercialization across Europe, retaining the European commercial organization built by BioCryst for operational continuity.

BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market

Despite the exclusion of European revenue after the close, BioCryst remains on track to meet the upper half of its 2025 revenue guidance range of $580 million to $600 million.

BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) is a biotechnology company that develops oral small-molecule and injectable protein therapeutics to treat rare diseases.

While we acknowledge the potential of BCRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.
[Source link]: https://finance.yahoo.com/news/biocryst-sells-european-orladeyo-business-205450678.html


[TITLE]Human Papilloma Virus/HPV Test and Pap Smear/Test Market worth US$3.94 billion by 2030 with 10.0% CAGR | MarketsandMarkets™:
[TEXT]
DELRAY BEACH, Fla., Oct. 4, 2025 /PRNewswire/ -- The global Human Papilloma Virus/HPV Test and Pap Smear/Test Market, valued at US$2.29 billion in 2024, stood at US$2.44 billion in 2025 and is projected to advance at a resilient CAGR of 10.0% from 2025 to 2030, culminating in a forecasted valuation of US$3.94 billion by the end of the period. Market growth is primarily driven by the rising number of HPV cases, which is closely linked to an increasing incidence of cervical cancer. This situation has created a strong demand for early detection and preventive testing. Additionally, the growing awareness of cervical cancer screening programs, supported by government initiatives and healthcare organizations, has encouraged more women to undergo routine tests, further boosting market adoption. Furthermore, the increase in research and development funding aimed at cervical cancer prevention has accelerated the creation of advanced and more accurate HPV testing methods, making diagnostics more accessible and reliable. Together, these factors are significantly contributing to market expansion.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=214207371

Browse in-depth TOC on " HPV Testing and Pap Test Market "

311 - Tables

53 - Figures

257 - Pages

By test type, the HPV testing and Pap test market is segmented into HPV testing and Pap tests. In 2024, HPV testing accounted for the dominant share of the market. This dominance is attributed to the growing global shift toward HPV testing as the primary screening method for cervical cancer, supported by its higher sensitivity and accuracy compared to Pap cytology alone. Regulatory bodies and health organizations, including the WHO, are increasingly recommending HPV-based screening protocols, which have accelerated adoption across both developed and emerging regions. The ability of HPV tests to detect high-risk viral strains before the development of precancerous lesions provides significant clinical value, driving their preference over traditional Pap tests. Additionally, advancements in molecular diagnostics, automation, and high-throughput platforms have further strengthened the position of HPV testing. While Pap tests continue to play an important role in many screening programs, the rising emphasis on early detection and prevention through molecular assays is ensuring HPV testing remains the dominant test type in the global market.

By care setting, the HPV testing and Pap test market is segmented into hospitals, diagnostic laboratories, and physicians' offices & clinics. Hospitals held the largest share of the market in 2024 and are also projected to register the fastest growth over the forecast period. This growth is driven by their ability to handle large-scale cervical cancer screening programs, supported by advanced infrastructure, trained specialists, and integrated diagnostic facilities. Hospitals are increasingly adopting molecular HPV testing platforms and automation technologies, which allow for high-throughput testing and enhanced accuracy. In addition, they serve as referral centers for complex cases and play a central role in organized national and regional screening initiatives, which continue to boost testing volumes. The increasing emphasis on preventive healthcare, coupled with hospital investments in digital pathology and data integration systems, is expected to further strengthen their role. These factors position hospitals as not only the dominant care setting but also the fastest-expanding segment in the global HPV testing and Pap test market.

By geography, the HPV testing and Pap test market has been segmented into five geographical regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the leading position in the HPV testing and Pap test market, supported by a strong healthcare infrastructure, established diagnostic networks, and strict regulatory standards that emphasize accuracy and reliability in testing. The region conducts a high volume of cervical cancer screenings each year, driven by growing awareness, preventive healthcare programs, and adoption of early detection initiatives. This fuels steady demand for consumables, reagents, and testing platforms that provide consistent results. Market growth is further supported by the presence of major global players in HPV and Pap testing, many of which are based in or have significant operations in North America. These companies invest in advanced molecular assays, automated testing systems, and digital tools that enhance efficiency and minimize errors. High healthcare spending, continuous R&D investment, and the rapid adoption of new diagnostic technologies collectively sustain North America's leadership in the global HPV testing and Pap test market.

Request Sample Pages : https://www.marketsandmarkets.com/requestsampleNew.asp?id=214207371

The major players operating in the HPV testing and Pap test market are Hologic, Inc. (US), Becton, Dickinson and Company (BD) (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Netherlands), Danaher Corporation (US), Abbott (US), Seegene Inc. (South Korea), SD Biosensor, INC. (South Korea), Sansure Biotech Inc. (China), ACON Laboratories, In. (US), Molbio Diagnostics Limited (India), Tellgen Corporation (China), Daan Gene Co., Ltd. (China), Jiangsu BioPerfectus Technologies Co., Ltd. (China), Anatolia Geneworks (Turkey), AB ANALITICA s.r.l. (Italy), CERTEST BIOTEC (Spain), Atila Biosystems (US), Yaneng BIOscience (Shenzhen) Co., Ltd. (China), Xiamen Zeesan Biotech Co., Ltd. (China), Advanced Molecular Diagnostics (AMD) (UK), Mylab Discovery Solutions Pvt. Ltd. (India), Sacace Biotechnologies Srl (Italy), Jiangsu Mole Bioscience Co., Ltd. (China), HANGZHOU ALLTEST BIOTECH CO., LTD. (China), Hangzhou Tongzhou Biotechnology Co., Ltd. (China), and Nanjing Liming Biological Products Co., Ltd. (China).

Hologic, Inc. (US):

Hologic, Inc. holds a leading position in the HPV testing and Pap test market, leveraging its strong expertise in women's health diagnostics and a comprehensive range of molecular assays and cytology solutions. The company's portfolio of FDA-approved HPV tests and Pap screening products is widely integrated into cervical cancer prevention programs, enabling accurate and reliable detection across diverse clinical settings. Hologic's global reach, backed by continuous innovation and regulatory approvals, has positioned it as a trusted partner for healthcare providers and laboratories. Its focus on improving diagnostic accuracy, advancing laboratory efficiency, and expanding access to high-quality women's health solutions highlights its leadership in this market. Additionally, the company's sustained investments in R&D, strategic partnerships, and customer-focused initiatives further reinforce its strong competitive advantage.

Becton, Dickinson and Company (US)

Becton, Dickinson and Company maintain a strong foothold in the HPV testing and Pap test market, supported by its wide-ranging diagnostic solutions and commitment to advancing women's health screening. The company provides molecular diagnostic assays and cytology-based screening products that ensure accuracy, consistency, and reliability in cervical cancer detection. Leveraging its global presence and expertise in sample collection systems, BD emphasizes innovation, regulatory compliance, and laboratory efficiency to meet the stringent needs of clinical settings. Its sustained focus on product development, R&D investment, and customer-driven strategies further strengthens its role as a key partner for laboratories worldwide.

F. Hoffmann-La Roche Ltd. (Switzerland)

F. Hoffmann-La Roche Ltd. is a prominent player in the HPV testing and Pap test market, recognized for its advanced molecular diagnostic tests and supporting systems designed for cervical cancer screening. The company provides high-quality, system-specific solutions that deliver precise and standardized results, helping laboratories achieve accuracy and efficiency in women's health diagnostics. Roche's strength lies in combining innovation with scalability, supported by its global presence, strong R&D capabilities, and emphasis on automation and digitalization. By continuously enhancing its diagnostic offerings and providing integrated solutions that streamline clinical workflows, Roche reinforces its leadership position in the market. Its reputation for scientific excellence, broad distribution network, and customer-focused approach further solidifies its standing as a trusted partner in HPV and Pap testing.
[Source link]: https://www.prnewswire.co.uk/news-releases/human-papilloma-virushpv-test-and-pap-smeartest-market-worth-us3-94-billion-by-2030-with-10-0-cagr--marketsandmarkets-302574741.html


[TITLE]Bank of America Issues Positive Forecast for Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Price:
[TEXT]
Amylyx Pharmaceuticals (NASDAQ:AMLX – Free Report) had its target price increased by Bank of America from $14.00 to $16.00 in a report published on Friday morning,Benzinga reports. Bank of America currently has a buy rating on the stock.

AMLX has been the topic of several other research reports. Jefferies Financial Group started coverage on shares of Amylyx Pharmaceuticals in a research note on Tuesday, June 24th. They issued a “hold” rating on the stock. Citigroup began coverage on Amylyx Pharmaceuticals in a report on Tuesday, June 17th. They set a “buy” rating and a $12.00 target price on the stock. Guggenheim increased their price target on Amylyx Pharmaceuticals from $17.00 to $25.00 and gave the company a “buy” rating in a research note on Monday, September 15th. UBS Group raised Amylyx Pharmaceuticals to a “hold” rating in a research note on Tuesday, June 24th. Finally, Wall Street Zen upgraded Amylyx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $14.75.

Get Amylyx Pharmaceuticals alerts:

Read Our Latest Research Report on Amylyx Pharmaceuticals

Amylyx Pharmaceuticals Price Performance

Amylyx Pharmaceuticals stock opened at $13.42 on Friday. The business has a 50 day moving average of $10.29 and a 200-day moving average of $7.00. The company has a market capitalization of $1.20 billion, a P/E ratio of -5.37 and a beta of -0.33. Amylyx Pharmaceuticals has a 1 year low of $2.60 and a 1 year high of $15.15.

Amylyx Pharmaceuticals (NASDAQ:AMLX – Get Free Report) last posted its earnings results on Thursday, August 7th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.02). Equities analysts anticipate that Amylyx Pharmaceuticals will post -2.2 EPS for the current year.

Insiders Place Their Bets

In other Amylyx Pharmaceuticals news, insider Camille L. Bedrosian sold 12,039 shares of the stock in a transaction that occurred on Tuesday, September 30th. The stock was sold at an average price of $14.58, for a total value of $175,528.62. Following the transaction, the insider owned 182,336 shares in the company, valued at approximately $2,658,458.88. This represents a 6.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO James M. Frates sold 10,558 shares of the firm’s stock in a transaction that occurred on Tuesday, September 30th. The shares were sold at an average price of $14.65, for a total value of $154,674.70. Following the completion of the sale, the chief financial officer directly owned 280,430 shares of the company’s stock, valued at $4,108,299.50. This trade represents a 3.63% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,333 shares of company stock valued at $1,319,495. 12.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Ameriprise Financial Inc. bought a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth
[Source link]: https://www.etfdailynews.com/2025/10/04/bank-of-america-issues-positive-forecast-for-amylyx-pharmaceuticals-nasdaqamlx-stock-price/


[TITLE]Citigroup Boosts Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $575.00:
[TEXT]
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective upped by equities researchers at Citigroup from $550.00 to $575.00 in a report issued on Thursday, Marketbeat reports. The firm presently has a “buy” rating on the pharmaceutical company’s stock. Citigroup’s price target would indicate a potential upside of 42.57% from the stock’s previous close.

Several other brokerages also recently commented on VRTX. Scotiabank reduced their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a research note on Tuesday, August 5th. Leerink Partnrs upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, September 25th. BMO Capital Markets set a $530.00 price objective on shares of Vertex Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Wells Fargo & Company raised shares of Vertex Pharmaceuticals from an “equal weight” rating to an “overweight” rating and set a $460.00 target price for the company in a report on Wednesday, August 6th. Finally, HC Wainwright decreased their price target on shares of Vertex Pharmaceuticals from $550.00 to $478.00 and set a “buy” rating on the stock in a research note on Tuesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $493.81.

Get Vertex Pharmaceuticals alerts:

Get Our Latest Stock Analysis on VRTX

Vertex Pharmaceuticals Price Performance

Vertex Pharmaceuticals stock opened at $403.30 on Thursday. The company’s 50-day moving average is $399.12 and its 200-day moving average is $442.98. The firm has a market capitalization of $103.40 billion, a PE ratio of 28.83 and a beta of 0.43. Vertex Pharmaceuticals has a fifty-two week low of $362.50 and a fifty-two week high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last posted its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 EPS for the quarter, topping analysts’ consensus estimates of $4.24 by $0.28. The business had revenue of $2.94 billion during the quarter, compared to analysts’ expectations of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.Vertex Pharmaceuticals’s quarterly revenue was up 11.3% on a year-over-year basis. During the same quarter last year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, analysts expect that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Insider Activity

In related news, Director Bruce I. Sachs purchased 5,000 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Wednesday, August 6th. The shares were acquired at an average price of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the transaction, the director directly owned 45,000 shares of the company’s stock, valued at $17,535,600. This represents a 12.50% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.20% of the company’s stock.

Institutional Trading of Vertex Pharmaceuticals

Several large investors have recently modified their holdings of VRTX. Brighton Jones LLC increased its holdings in Vertex Pharmaceuticals by 15.0% in the 4th quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock valued at $1,783,000 after buying an additional 579 shares during the period. NBC Securities Inc. acquired a new stake in shares of Vertex Pharmaceuticals during the 1st quarter worth approximately $167,000. Merit Financial Group LLC increased its stake in Vertex Pharmaceuticals by 10.1% in the first quarter. Merit Financial Group LLC now owns 5,427 shares of the pharmaceutical company’s stock valued at $2,631,000 after acquiring an additional 496 shares during the last quarter. RFG Advisory LLC raised its position in Vertex Pharmaceuticals by 12.1% during the first quarter. RFG Advisory LLC now owns 757 shares of the pharmaceutical company’s stock valued at $367,000 after purchasing an additional 82 shares in the last quarter. Finally, Secure Asset Management LLC acquired a new position in Vertex Pharmaceuticals during the first quarter valued at approximately $224,000. 90.96% of the stock is owned by institutional investors and hedge funds.
[Source link]: https://www.etfdailynews.com/2025/10/04/citigroup-boosts-vertex-pharmaceuticals-nasdaqvrtx-price-target-to-575-00/


===== Company info for companies mentioned in news =====

Company name: amylyx pharmaceuticals
name: amylyx pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=amylyx+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: biocryst pharmaceuticals
name: biocryst pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=biocryst+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

Company name: marketsandmarkets
name: marketsandmarkets
symbol: None
note: no reliable listing found
------------------------------------------------------------------

Company name: vertex pharmaceuticals
name: vertex pharmaceuticals
symbol: None
error: 422 Client Error: Unprocessable Entity for url: https://finnhub.io/api/v1/search?q=vertex+pharmaceuticals&token=d36pnjpr01qtvbtinv3gd36pnjpr01qtvbtinv40
------------------------------------------------------------------

================================================================================

[TITLE]European healthcare stocks surge as U.S. Pfizer deal reduces some uncertainty:
[TEXT]

[Source link]: https://biztoc.com/x/160dbf9a05091978


===== Company info for companies mentioned in news =====

Company name: pfizer
symbol: PFE
market_cap: None
pe: None
enterprise_value: None
ebitda: None
revenue: None
net_income: None
cap_bucket: None
as_of: 1759716027
name: pfizer
------------------------------------------------------------------

================================================================================

